Loxo reports updated Phase I data for RET inhibitor

Loxo Oncology Inc. (NASDAQ:LOXO) reported updated response data on Saturday at the American Society of Clinical Oncology meeting in Chicago from the Phase I LIBRETTO-001 trial evaluating

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE